APA (7th ed.) Citation

MF, C., Z, S., HA, Y., LV, S., CM, L., EP, M., . . . KT, F. (2024). Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E. JCO precision oncology, 8, e2300454. https://doi.org/10.1200/PO.23.00454

Chicago Style (17th ed.) Citation

MF, Chen, et al. "Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E." JCO Precision Oncology 8 (2024): e2300454. https://doi.org/10.1200/PO.23.00454.

MLA (9th ed.) Citation

MF, Chen, et al. "Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E." JCO Precision Oncology, vol. 8, 2024, p. e2300454, https://doi.org/10.1200/PO.23.00454.